Free Trial
NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

RenovoRx logo
$1.14 -0.06 (-5.00%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.14 0.00 (0.00%)
As of 08/8/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About RenovoRx Stock (NASDAQ:RNXT)

Key Stats

Today's Range
$1.11
$1.22
50-Day Range
$1.14
$1.42
52-Week Range
$0.75
$1.69
Volume
194,041 shs
Average Volume
105,607 shs
Market Capitalization
$41.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25
Consensus Rating
Buy

Company Overview

RenovoRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

RNXT MarketRank™: 

RenovoRx scored higher than 53% of companies evaluated by MarketBeat, and ranked 483rd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    RenovoRx has only been the subject of 2 research reports in the past 90 days.

  • Read more about RenovoRx's stock forecast and price target.
  • Earnings Growth

    Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of RenovoRx is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of RenovoRx is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    RenovoRx has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about RenovoRx's valuation and earnings.
  • Percentage of Shares Shorted

    0.33% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently decreased by 37.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    RenovoRx does not currently pay a dividend.

  • Dividend Growth

    RenovoRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.33% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently decreased by 37.44%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    RenovoRx has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for RenovoRx this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for RNXT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,400.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 9.13% of the stock of RenovoRx is held by insiders.

  • Percentage Held by Institutions

    Only 3.10% of the stock of RenovoRx is held by institutions.

  • Read more about RenovoRx's insider trading history.
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RNXT Stock News Headlines

RenovoRx (NASDAQ:RNXT) Stock Rating Lowered by Wall Street Zen
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
See More Headlines

RNXT Stock Analysis - Frequently Asked Questions

RenovoRx's stock was trading at $1.29 at the start of the year. Since then, RNXT shares have decreased by 11.6% and is now trading at $1.14.

RenovoRx, Inc. (NASDAQ:RNXT) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.23 million.
Read the conference call transcript
.

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC acted as the underwriters for the IPO.

Top institutional shareholders of RenovoRx include Geode Capital Management LLC (0.97%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms.
View institutional ownership trends
.

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

Last Earnings
5/15/2025
Today
8/10/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNXT
CIK
1574094
Employees
6
Year Founded
N/A

Price Target and Rating

High Price Target
$11.50
Low Price Target
$3.00
Potential Upside/Downside
+536.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.81 million
Net Margins
N/A
Pretax Margin
-4,232.50%
Return on Equity
-119.58%
Return on Assets
-88.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.07
Quick Ratio
9.07

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
1,042.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
6.00

Miscellaneous

Outstanding Shares
36,570,000
Free Float
33,233,000
Market Cap
$41.69 million
Optionable
Not Optionable
Beta
1.26

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:RNXT) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners